Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd Share Price Today: Live Updates & Key Insights
Get insights on Torrent Pharmaceuticals Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Torrent Pharmaceuticals Ltd Share Price Chart
Torrent Pharmaceuticals Ltd Fundamentals
Traded Volume: 94,430
Market Cap(Cr): 1,21,158
Avg Traded Price 796.68
1 Year return 11.53%
Upper Circuit 3,592
Lower Circuit 3,543.3
P/E TTM 57.00
P/B Ratio 63.00
Traded Value(Cr) 3380.59
EPS TTM 63.230
Book value 63.230
Dividend 1.00%
Torrent Pharmaceuticals Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Torrent Pharmaceuticals Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Torrent Pharmaceuticals Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -0.62%
1M +1.53%
3M +1.59%
1Y +11.53%
YTD +3.94%
Torrent Pharmaceuticals Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Torrent Pharmaceuticals Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 1.74L
Day Before Yesterday 1.95L
1W Avg 2.21L
1M Avg 1.83L
3M Avg 2.33L
Torrent Pharmaceuticals Ltd Technical Details
Torrent Pharmaceuticals Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 3552
Support 2 3523
Support 3 3503
Pivot Point : 3572
Resistance 1 3600
Resistance 2 3620
Resistance 3 3649
Torrent Pharmaceuticals Ltd Corporate Actions
Torrent Pharmaceuticals Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Torrent Pharmaceuticals Ltd’s capital allocation strategies.
All
Ex-Date 20-Jun-2025 Type D Description 6.00/share@120.00% Record Date 20-Jun-2025 Ratio 120.00
Ex-Date 31-Jan-2025 Type D Description 26.00/share@520.00% Record Date 01-Feb-2025 Ratio 520.00
Ex-Date 21-Jun-2024 Type D Description 6.00/share@120.00% Record Date 21-Jun-2024 Ratio 120.00
Ex-Date 12-Feb-2024 Type D Description 22.00/share@440.00% Record Date 12-Feb-2024 Ratio 440.00
Ex-Date 23-Jun-2023 Type D Description 8.00/share@160.00% Record Date 23-Jun-2023 Ratio 160.00
Ex-Date 03-Feb-2023 Type D Description 14.00/share@280.00% Record Date 03-Feb-2023 Ratio 280.00
Ex-Date 08-Jul-2022 Type B Description share@1:1 Record Date 11-Jul-2022 Ratio 1:1
Ex-Date 03-Jun-2022 Type D Description 15.00/share@300.00% Record Date 06-Jun-2022 Ratio 300.00
Ex-Date 03-Jun-2022 Type D Description 8.00/share@160.00% Record Date 06-Jun-2022 Ratio 160.00
Ex-Date 02-Feb-2022 Type D Description 25.00/share@500.00% Record Date 03-Feb-2022 Ratio 500.00
Ex-Date 17-Jun-2021 Type D Description 15.00/share@300.00% Record Date 18-Jun-2021 Ratio 300.00
Ex-Date 15-Feb-2021 Type D Description 20.00/share@400.00% Record Date 16-Feb-2021 Ratio 400.00
Ex-Date 18-Mar-2020 Type D Description 17.00/share@340.00% Record Date 19-Mar-2020 Ratio 340.00
Ex-Date 18-Mar-2020 Type D Description 15.00/share@300.00% Record Date 19-Mar-2020 Ratio 300.00
Ex-Date 13-Jun-2019 Type D Description 4.00/share@80.00% Record Date 14-Jun-2019 Ratio 80.00
Ex-Date 06-Feb-2019 Type D Description 13.00/share@260.00% Record Date 07-Feb-2019 Ratio 260.00
Ex-Date 18-Jun-2018 Type D Description 5.00/share@100.00% Record Date 07-Nov-2025 Ratio 100.00
Ex-Date 15-Feb-2018 Type D Description 9.00/share@180.00% Record Date 19-Feb-2018 Ratio 180.00
Ex-Date 19-Jun-2017 Type D Description 4.00/share@80.00% Record Date 07-Nov-2025 Ratio 80.00
Ex-Date 10-Feb-2017 Type D Description 10.00/share@200.00% Record Date 13-Feb-2017 Ratio 200.00
Ex-Date 16-Mar-2016 Type D Description 15.00/share@300.00% Record Date 17-Mar-2016 Ratio 300.00
Ex-Date 11-Feb-2016 Type D Description 20.00/share@400.00% Record Date 12-Feb-2016 Ratio 400.00
Ex-Date 15-Jun-2015 Type D Description 6.25/share@125.00% Record Date 07-Nov-2025 Ratio 125.00
Ex-Date 02-Feb-2015 Type D Description 5.00/share@100.00% Record Date 03-Feb-2015 Ratio 100.00
Ex-Date 16-Jun-2014 Type D Description 5.00/share@100.00% Record Date 07-Nov-2025 Ratio 100.00
Ex-Date 24-Jan-2014 Type D Description 5.00/share@100.00% Record Date 27-Jan-2014 Ratio 100.00
Ex-Date 23-Jul-2013 Type B Description share@1:1 Record Date 24-Jul-2013 Ratio 1:1
Ex-Date 10-Jun-2013 Type D Description 10.00/share@200.00% Record Date 07-Nov-2025 Ratio 200.00
Ex-Date 10-Jun-2013 Type D Description 7.00/share@140.00% Record Date 07-Nov-2025 Ratio 140.00
Ex-Date 01-Feb-2013 Type D Description 6.00/share@120.00% Record Date 04-Feb-2013 Ratio 120.00
Ex-Date 11-Jun-2012 Type D Description 2.50/share@50.00% Record Date 07-Nov-2025 Ratio 50.00
Ex-Date 27-Jan-2012 Type D Description 6.00/share@120.00% Record Date 30-Jan-2012 Ratio 120.00
Ex-Date 06-Jun-2011 Type D Description 6.00/share@120.00% Record Date 07-Nov-2025 Ratio 120.00
Ex-Date 06-Jun-2011 Type D Description 2.00/share@40.00% Record Date 07-Nov-2025 Ratio 40.00
Ex-Date 04-Jun-2010 Type D Description 6.00/share@120.00% Record Date 07-Nov-2025 Ratio 120.00
Ex-Date 08-Jun-2009 Type D Description 4.00/share@80.00% Record Date 07-Nov-2025 Ratio 80.00
Ex-Date 19-Jun-2008 Type D Description 3.50/share@70.00% Record Date 07-Nov-2025 Ratio 70.00
Ex-Date 23-Mar-2007 Type D Description 3.00/share@60.00% Record Date 26-Mar-2007 Ratio 60.00
Dividends
Announcement Date 20-Jun-2025 Ex Dividend Date 20-Jun-2025 Dividend(%) 120
Announcement Date 31-Jan-2025 Ex Dividend Date 31-Jan-2025 Dividend(%) 520
Announcement Date 21-Jun-2024 Ex Dividend Date 21-Jun-2024 Dividend(%) 120
Announcement Date 12-Feb-2024 Ex Dividend Date 12-Feb-2024 Dividend(%) 440
Announcement Date 23-Jun-2023 Ex Dividend Date 23-Jun-2023 Dividend(%) 160
Announcement Date 03-Feb-2023 Ex Dividend Date 03-Feb-2023 Dividend(%) 280
Announcement Date 03-Jun-2022 Ex Dividend Date 03-Jun-2022 Dividend(%) 300
Announcement Date 03-Jun-2022 Ex Dividend Date 03-Jun-2022 Dividend(%) 160
Announcement Date 02-Feb-2022 Ex Dividend Date 02-Feb-2022 Dividend(%) 500
Announcement Date 17-Jun-2021 Ex Dividend Date 17-Jun-2021 Dividend(%) 300
Announcement Date 15-Feb-2021 Ex Dividend Date 15-Feb-2021 Dividend(%) 400
Announcement Date 18-Mar-2020 Ex Dividend Date 18-Mar-2020 Dividend(%) 300
Announcement Date 18-Mar-2020 Ex Dividend Date 18-Mar-2020 Dividend(%) 340
Announcement Date 13-Jun-2019 Ex Dividend Date 13-Jun-2019 Dividend(%) 80
Announcement Date 06-Feb-2019 Ex Dividend Date 06-Feb-2019 Dividend(%) 260
Announcement Date 18-Jun-2018 Ex Dividend Date 18-Jun-2018 Dividend(%) 100
Announcement Date 15-Feb-2018 Ex Dividend Date 15-Feb-2018 Dividend(%) 180
Announcement Date 19-Jun-2017 Ex Dividend Date 19-Jun-2017 Dividend(%) 80
Announcement Date 10-Feb-2017 Ex Dividend Date 10-Feb-2017 Dividend(%) 200
Announcement Date 16-Mar-2016 Ex Dividend Date 16-Mar-2016 Dividend(%) 300
Announcement Date 11-Feb-2016 Ex Dividend Date 11-Feb-2016 Dividend(%) 400
Announcement Date 15-Jun-2015 Ex Dividend Date 15-Jun-2015 Dividend(%) 125
Announcement Date 02-Feb-2015 Ex Dividend Date 02-Feb-2015 Dividend(%) 100
Announcement Date 16-Jun-2014 Ex Dividend Date 16-Jun-2014 Dividend(%) 100
Announcement Date 24-Jan-2014 Ex Dividend Date 24-Jan-2014 Dividend(%) 100
Announcement Date 10-Jun-2013 Ex Dividend Date 10-Jun-2013 Dividend(%) 200
Announcement Date 10-Jun-2013 Ex Dividend Date 10-Jun-2013 Dividend(%) 140
Announcement Date 01-Feb-2013 Ex Dividend Date 01-Feb-2013 Dividend(%) 120
Announcement Date 11-Jun-2012 Ex Dividend Date 11-Jun-2012 Dividend(%) 50
Announcement Date 27-Jan-2012 Ex Dividend Date 27-Jan-2012 Dividend(%) 120
Announcement Date 06-Jun-2011 Ex Dividend Date 06-Jun-2011 Dividend(%) 40
Announcement Date 06-Jun-2011 Ex Dividend Date 06-Jun-2011 Dividend(%) 120
Announcement Date 04-Jun-2010 Ex Dividend Date 04-Jun-2010 Dividend(%) 120
Announcement Date 08-Jun-2009 Ex Dividend Date 08-Jun-2009 Dividend(%) 80
Announcement Date 19-Jun-2008 Ex Dividend Date 19-Jun-2008 Dividend(%) 70
Announcement Date 23-Mar-2007 Ex Dividend Date 23-Mar-2007 Dividend(%) 60
Bonus
Record Date 11-Jul-2022 Ex-Bonus Date 08-Jul-2022 Ratio 1:1
Record Date 24-Jul-2013 Ex-Bonus Date 23-Jul-2013 Ratio 1:1
Splits
No Split has been declared by TORNTPHARM
Others
Rights No Rights has been declared by TORNTPHARM
Torrent Pharmaceuticals Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Torrent Pharmaceuticals Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Torrent Pharmaceuticals Ltd's relative performance and valuation against major competitors.
Stock Name Sun Pharmaceutical Industries Ltd ₹1691.40 (+0.33%) M. Cap (Cr) 4058.24 1 Yr Return (%) -7.44% P/E (TTM) 38.84 PB Ratio 5.62
Stock Name Divis Laboratories Ltd ₹6656.50 (-3.30%) M. Cap (Cr) 1767.09 1 Yr Return (%) +11.80% P/E (TTM) 71.11 PB Ratio 11.80
Stock Name Cipla Ltd ₹1505.70 (+0.28%) M. Cap (Cr) 1216.26 1 Yr Return (%) -5.54% P/E (TTM) 22.35 PB Ratio 3.90
Stock Name Torrent Pharmaceuticals Ltd ₹3580.00 (+0.75%) M. Cap (Cr) 1211.58 1 Yr Return (%) +11.53% P/E (TTM) 56.62 PB Ratio 16.15
Stock Name Dr Reddys Laboratories Ltd ₹1205.40 (+0.02%) M. Cap (Cr) 1006.04 1 Yr Return (%) -7.43% P/E (TTM) 17.43 PB Ratio 3.00
Stock Name Zydus Lifesciences Ltd ₹944.10 (+0.79%) M. Cap (Cr) 949.99 1 Yr Return (%) -5.13% P/E (TTM) 19.30 PB Ratio 3.97
Stock Name Mankind Pharma Ltd ₹2261.80 (-2.05%) M. Cap (Cr) 933.58 1 Yr Return (%) -17.72% P/E (TTM) 53.32 PB Ratio 6.51
Torrent Pharmaceuticals Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Torrent Pharmaceuticals Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 2574.50 Mar 2024 2893.10 Mar 2023 2265.41 Mar 2022 2140.10 Mar 2021 1578.23
PARTICULARS Investing Activities Mar 2025 -470.09 Mar 2024 -296.07 Mar 2023 -2384.07 Mar 2022 -159.70 Mar 2021 -316.28
PARTICULARS Financing Activities Mar 2025 -2104.46 Mar 2024 -2577.57 Mar 2023 80.74 Mar 2022 -1977.27 Mar 2021 -1586.54
PARTICULARS Net Cash Flow Mar 2025 -0.05 Mar 2024 19.46 Mar 2023 20.40 Mar 2022 3.13 Mar 2021 -324.59
Torrent Pharmaceuticals Ltd Shareholding Pattern
This shows the ownership breakdown of Torrent Pharmaceuticals Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 68.31%
Public 6.47%
Other Institutions 4.15%
FII 15.92%
Mutual Funds 5.12%
About Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Limited is a leading player in the Indian pharmaceutical sector, concentrating on the chronic and sub-chronic therapeutic segments. The Company has established itself as a leader in developing niche pharmaceutical solutions through its patient-centric innovation. The Company is a dominant player in the therapeutic areas of Cardiovascular (CV), Central Nervous System (CNS), Vitamins and Nutrients (VMN), Gastro-Intestinal (GI) and Anti-Diabetes (AD) therapies in India. It has a strong international presence across more than 40 countries with operations in regulated and emerging markets, such as the US, Europe, Germany, Brazil and Rest of the World. The Company operates through its wholly-owned subsidiaries spread across 15 countries with major setups in the US, Germany and Brazil. Torrent Pharmaceuticals Limited was founded in 1959 as Trinity Laboratories by Late Shri U. N. Mehta. Trinity was later renamed as Torrent Pharmaceuticals Limited and taken public on July 15, 1972. In 1980, Company started their first manufacturing facility at Vatva and received first export order in 1983. In 1986, it started second manufacturing plant at Chhatral. In 1995, Torrent Gujarat Biotech Limited's plant was commissioned.In the year 1996, the company acquired the Pharma related investments and business of Torrent Exports Ltd and also commissioned the state-of-the-art R&D centre. In the year 1997, India Infusions Ltd was merged with the company. As a part of restructuring, the company formed three new divisions namely, Prima, Vista and Psycan in the year 1999. During the year 2001-02, the company launched 31 new products, out of which 8 were first time launches in India. The company completed the upgradation and modernization programme for the formulations plant at the total cost of Rs 48 crore. Also, they acquired a small pharmaceutical company, namely Fornex Industrial Farmaceutica Ltda, later renamed as Torrent Do Brasil Ltda, in Brazil for Rs 128 lakh. During the year, the company divested their entire 50% equity stake in Sanofi Torrent (India) Ltd to their joint venture partner Sanofi Synthelabo, France. Also, they transferred their entire equity holding of 1,95,04,691 shares in the sick industrial undertaking Torrent Gujarat Biotech Ltd to Torrent Pvt Ltd, a company belonging to the promoter group. During the year 2002-03, the company introduced 28 new products including the line extensions. The company completed the upgradation of bulk drug plant during the year, which was started during the financial year 2001-02. Also, the company incorporated Torrent Pharma GmbH as a wholly owned subsidiary company in Germany.During the year 2003-04, the company set up a wholly owned subsidiary company, namely Torrent Pharma Inc in USA with the objective of business development in the large, growing and highly profitable North America generic market. Also, they introduced 25 new products during the year.Torrent Pharma's presence in Germany started with the acquisition of Heumann Pharma from Pfizer in 2004-05. The Company entered into a License Agreement with Novartis granting global rights for further development and commercialization of its patented AGE Breaker Compound to Novartis. Also, they signed research collaboration agreement with AstraZeneca, another leading global pharmaceuticals company with the aim of discovering a novel drug candidate for the treatment of hypertension. The company incorporated Torrent Pharma Philippines Inc as a wholly owned subsidiary in the Philippines, with a view to tap the huge potential in Philippines.During the year 2005-06, the company successfully completed capacity expansion and consolidation of bulk drug plant at manufacturing unit in Indrad. The company entered into an agreement with Novo Nordisk India Pvt Ltd, a wholly owned subsidiary of Novo Nordisk A/S, Denmark to extend existing contract manufacturing arrangement for manufacture of Human Insulin formulations. During the year, the company introduced 43 new products in the market. Also, the company launched new divisions AXON and NEURON and expanded their field force in order to tap increasing business opportunities in CNS segment. In April 2006, they launched a new division 'PSYCAN AZUCA' to exclusively cater to the needs of the significant and growing diabetes population in the country.During the year, the company acquired Heumann Pharma GmbH & Co Generica KG (Heumann) of Germany for a cash consideration of euro 3.31 million (Rs.17.20 crores). Heumann, is engaged in the business of marketing generic medicines in Germany under the brand name 'Heumann'. In March 2006, the company incorporated Laboratorios Torrent SA de CV to seek registrations of their products in Mexico and subsequently launch a basket of products in the cardiovascular, central nervous system and oral anti-diabetes area. In April 2006, the company incorporated Torrent Pharma Japan Co Ltd as a wholly owned subsidiary in Japan, to cover the generic market in the country effectively for future business prospects.During the year 2006-07, the company launched 49 new products in the market. The manufacturing facilities at Chatral received approval from the US Food and Drug Administration for the API (active pharmaceutical ingredient) and oral solid dosage formulations facilities. The company initiated process of setting up of a new Greenfield manufacturing site in the state of Sikkim to support the growth in domestic market. Also, the company incorporated a subsidiary in Mexico, named Laboratorios Torrent SA de CV, as a first step for entry into the lucrative Mexican market.During the year 2007-08, the company launched 52 new products in the market. They successfully entered the highly competitive US market with launch of Citalopram. During the year, the company undertook capacity expansion of 30% in tablet formulations at Baddi plant and the project is nearing completion. They also completed development for nine molecules for the European Union market and nine molecules for United States market.During the year 2008-09, the company made an investment of Rs 2.05 crore in the equity shares of their wholly owned subsidiary Laboratories Torrent, SA De CV, in Mexico. In September 2008, the company received the US Food and Drug Administration approval for anti-hypertension drug amlodipine besylate tablets in multiple strengths and in November 2008, their generic, risperidone, in tablet forms of various strengths, also got the approval.In 2009, Torrent Pharmaceuticals commissioned a dedicated formulation and packaging unit for manufacturing insulin exclusively for Novo Nordisk. During the year under review, the company entered into license and supply agreement with AstraZeneca for marketing its products in international market.In 2010, Torrent Pharmaceuticals' Baddi plant received OHAS Audit 18001:2007certification. During the year under review, the Baddi facility was approved by the regulatory authority of Uganda. During the year under review, Torrent Pharmaceuticals forayed into the therapeutic areas of gynaecology and oncology. During the year under review, Torrent Pharmaceuticals commissioned a subsidiary in United Kingdom and Romania. During the year under review, Torrent Research Center developed Long Acting Injectables technology.In 2011, Torrent Pharmaceuticals' Sikkim plant commenced operation. During the year under review, Torrent Research Center developed indigenous Nasal Drug Delivery system. During the year under review, Torrent Pharmaceuticals set up Sparsh, a dedicated division to cater to Dermatology segment.In 2013, Torrent Pharmaceuticals entered into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab.In 2014, Torrent Pharmaceuticals acquired Elder Pharma's identified Indian branded formulation business in India and Nepal. During the year under review, the company launched Nephro, a dedicated division to cater to the Nephrology segment. During the year under review, Torrent Pharmaceuticals' Dahej plant commenced operations.In 2015, Torrent Pharmaceuticals acquired 100% stake of Zyg Pharma, a company engaged in manufacturing various dermatological formulations like creams, ointments, gels, lotions, solutions. In 2016, Torrent Pharmaceuticals' Dahej plant received USFDA approval. During the year under review, the company acquired API manufacturing unit of Hyderabad based Glochem Industries Limited.In 2017, Torrent Pharmaceuticals acquired Unichem's domestic and Nepal business and also its Sikkim manufacturing facility. During the year under review, the company acquired women healthcare brands from Novartis.In 2018, Torrent Pharmaceuticals acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.As of 31st March, 2019, the Company has 16 subsidiaries, out of which 4 are step down subsidiaries. Bio-Pharm Inc., a wholly owned subsidiary of Torrent Pharma Inc. USA (TPI) merged with TPI with effect from 1st January, 2019. The merger aims at administrative convenience and to achieve higher operational efficiencies. As of 31st March, 2020, the Company has 15 subsidiaries, out of which 3 are step down subsidiaries. Aptil Pharma Limited, a wholly owned subsidiary of Torrent Pharma (UK) Limited., UK dissolved w.e.f. 15th October, 2019 and consequently, the business of Aptil was merged into Torrent Pharma (UK) Limited.During year 2021, Company launched Dapagliflozin & Rivaroxaban in the Cardiovascular therapy, Brivaracetam in the Central Nervous System therapy, Obeticholic Acid within the Gastro Intestinal therapy and NDDS Tapentadol Nasal spray in Pain Analgesic therapy.During the year 2021-22 , TPL (Malta) Limited, wholly owned subsidiary of the Company and Torrent Pharma (Malta) Limited wholly owned subsidiary of TPL (Malta) Limited were incorporated on 17th August, 2021. During the year 2022-23, the Company acquired 100% of the equity shares of Curatio Health Care (I) Private Limited (CHPL) and its two wholly owned subsidiaries, at Philippines and Sri Lanka for a total consideration costing Rs. 2000 Crores. Accordingly, Curatio Health Care (I) Private Limited (CHPL) was amalgamated with the Parent Company effective from 14th October, 2022, the Appointed Date. The Company launched 6 products in the CNS, diabetic and cardio segments with Rivaroxaban and Desvenlafaxine being the two biggest success in 2023. In 2024, Company launched its first oncology product in the US market from its new Bileshwarpura facility and commenced commerical operations. It entered into strategic alliance with Zydus Lifesciences Ltd to strengthen the gastroenterology portfolio while addressing the growing patients' needs in NASH & NAFLD. The Company has strategically diversified and strengthened its presence in some of the key therapies linked to patent expiries like Sitagliptin and its Fixed Dose Combinations (FDC), Linagliptin and its FDC in the anti-diabetic segment, Ferric Carboxy Maltose in gynecology therapy and Lasmitidan in the CNS segment. Further, it has entered high potential market of Sodium Alginate, Imeglimin, Brivaracetam SR and Digestive Enzyme market to cater to unmet therapy needs and launched several brand extensions.The Company launched Saroglitazar Magnesium franchise under the brand 'Vorxarr' in 2025. Further, it launched novel class of drugPCAB (potassium competitive acid blocker) Vonoprazan under brand name Kabvie in June 2024, making it a market leader in FY 2025. Launched Shelcal Pro Adult Gummies, as a calcium supplement in April, 2024. Launched the first oncology drug in the US market in FY25.
Chairman Emeritus
Sudhir Mehta
Registered office Torrent House, Off Ashram Road, Ahmedabad, Gujarat, 380009
FAX :91-79-26599000
Background
Incorporation Year 1972
Face Value ₹5.00
Market Lot 1
FAQs on Torrent Pharmaceuticals Ltd
How to buy Torrent Pharmaceuticals Ltd shares on NSE?
To buy Torrent Pharmaceuticals Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Torrent Pharmaceuticals Ltd share price today?
The Torrent Pharmaceuticals Ltd share price on NSE is ₹3580.00 today.
What is the market cap of Torrent Pharmaceuticals Ltd on NSE?
The company has a market capitalization of ₹121158.02.
What is the PE & PB ratio of Torrent Pharmaceuticals Ltd?
PE is 57 and PB is 63.
What is the 52 Week High and Low of Torrent Pharmaceuticals Ltd shares?
Torrent Pharmaceuticals Ltd stock price high: ₹3787.90 Torrent Pharmaceuticals Ltd stock price low: ₹2886.45.
What elements affect the price of Torrent Pharma shares?
The elements affecting the price of Torrent Pharma shares include the following –
What is Torrent Pharma's potential for long-term growth?
Torrent Pharma’s share price fluctuates daily. As of 10th May 2023, the 52-week high and low was recorded at 1722.70 and 1242.50, respectively. The lower and upper circuits were recorded at 1484.45 and 1814.25, respectively.
What is the Torrent Pharma share's impending dividend?
On 25th January 2023, Torrent Pharma declared an interim dividend of 14 per share. The ex-dividend date is 3rd February 2023. This was the company's last dividend declaration.
How frequently are dividends paid on shares of Torrent Pharma?
The frequency of dividend payments depends on the company’s financial performance. Torrent Pharma has paid two or more dividends in a year comprising the interim, special, and final dividends. Have a look –
Are bonus shares being offered by Torrent Pharma?
Currently, Torrent Pharma is not offering any bonus shares. However, it offered such shares in May 2022. One bonus share was offered for each share held by the investor.